Patritumab deruxtecan extends PFS vs. chemotherapy in advanced non-small cell lung cancer
Click Here to Manage Email Alerts
Patritumab deruxtecan improved PFS compared with chemotherapy among certain patients with advanced non-small cell lung cancer, according to the agent’s manufacturer.
Patritumab deruxtecan (HER3-DXd; Daiichi Sankyo, Merck) is a HER3-directed antibody-drug conjugate in development for patients with metastatic or locally advanced EGFR-mutated NSCLC who progressed on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies.
Patients who fail EGFR TKIs often receive platinum-based chemotherapy and subsequent salvage therapies, but PFS typically is short.
The open-label, phase 3 HERTHENA-Lung02 trial evaluated the efficacy and safety of patritumab deruxtecan compared with pemetrexed and platinum chemotherapy.
All 586 trial participants had metastatic or locally advanced NSCLC with EGFR-activating mutations, and they all had received third-generation EGFR TKI therapy.
Researchers randomly assigned patients to 5.6 mg/kg patritumab deruxtecan every 3 weeks or four cycles of pemetrexed and platinum induction chemotherapy. Patients in the chemotherapy group who completed induction chemotherapy and had no disease progression could continue treatment with maintenance pemetrexed. Trial protocol placed no restriction on the number of maintenance pemetrexed cycles.
PFS served as the primary endpoint. OS, objective response rate, duration of response, clinical benefit rate, time to response, disease control rate and safety served as secondary endpoints.
Results showed a significant improvement in PFS with patritumab deruxtecan. OS results remained immature at the time of analysis.
Patritumab deruxtecan exhibited a safety profile consistent with that observed in prior trials. Investigators observed no new safety signals.
Two patients in the trial died due to interstitial lung disease events, according to a Merck press release. Most interstitial lung disease events were grade 1 or grade 2, the release stated.
Complete results from HERTHENA-Lung02 will be presented at a medical meeting.
Read more about
Click Here to Manage Email Alerts